[{"orgOrder":0,"company":"Passkey Therapeutics","sponsor":"Breakout Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Synergistic Multifunctional Therapeutics","moa":"","graph1":null,"graph2":null,"graph3":"Passkey Therapeutics","amount2":0.02,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Passkey Therapeutics \/ Breakout Ventures","highestDevelopmentStatusID":null,"companyTruncated":"Passkey Therapeutics \/ Breakout Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Passkey Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The funding will support Passkey’s development of SMThs, a new class of single-drug therapies designed to modulate rare combinations of proteins that work together.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Synergistic Multifunctional Therapeutics

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Breakout Ventures

                          Deal Size : $20.0 million

                          Deal Type : Financing

                          blank